Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2395 • ACR Convergence 2024
Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Antônio Silaide De Araújo-Júnior¹, Emília Sato², Alexandre Wagner Silva de Souza¹, Fábio Jennings¹, Gianna Mastroianni Kirsztajn³, Ricardo Sesso³ and Edgard Reis Neto⁴, ¹Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Division of Nephrology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ⁴Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…
Abstract Number: 2413 • ACR Convergence 2024
The Natural History of SLE Has Changed Since the 1970s
Adaobi Ugochukwu¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: We investigated the changes in the prevalence of specific SLE manifestations over the last 50 years. In addition, we looked for differences between African-Americans…
Abstract Number: 2429 • ACR Convergence 2024
Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
Carmen Raya-Santos¹, José Rosas-Gómez de Salazar², Mariana Marco³, Ana Pons-Bas³, Rocío Gallego Campuzano⁴, Juan Carlos Cortes⁴, Lara Pons-Canet³, Maruan Shalabi³, José Miguel Senabre³, José Antonio Bernal⁵, Gregorio Santos-Soler⁶, Xavier Barber⁷ and Jose Alberto Garcia Gomez⁷, ¹Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ³Hospital Marina Baixa, Villajoyosa, Spain, ⁴Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, ⁵Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁶Hospital Marina Baixa, Villajoyosa, ⁷Miguel Hernandez University, Villajoyosa, Spain
Background/Purpose: The administration of hydroxychloroquine-sulphate (HCQ) can lead to the risk of QTc prolongation and cardiac arrhythmias. We evaluated the HCQ concentration and the incidence…
Abstract Number: 2575 • ACR Convergence 2024
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Paola Vidal¹, Javier Narvaez-García², Francesc-Xavier Fulladosa², Francesca Mitjavila², olga Capdevila², Pol Maymó³, Judith Palacios⁴ and Joan Miquel Nolla², ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
Abstract Number: 2626 • ACR Convergence 2024
Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion
Nicholas C Chan¹, Nicholas Gold², Deborah Levy², Andrea Knight³, Earl Silverman⁴, Daniela Dominguez⁵, Lawrence Ng², Lauren Erdman² and Linda Hiraki², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Silverman, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) is a clinically heterogeneous autoimmune disease. We hypothesized that similarity network fusion (SNF) a data driven method would identify…
Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0177 • ACR Convergence 2024
Rural-urban Disparities in the Myocardial Infarction Hospitalizations in People with Systemic Lupus Erythematosus in the US
Sumanth Chandrupatla¹ and Jasvinder Singh², ¹University of Alabama at Birmingham, Birmingham, AL, ²Baylor College of Medicine, Birmingham, AL
Background/Purpose: To assess whether rural-urban disparities exist in people with SLE for hospitalization with myocardial infarction (MI)Methods: We used the 2016-2019 U.S. National Inpatient Sample…
Abstract Number: 0205 • ACR Convergence 2024
Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE)…
Abstract Number: 0424 • ACR Convergence 2024
The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE
Catherine Sims¹, Amanda Eudy², Samir Soneji³, Kateena Addae-Konadu³, Jennifer Gilner³, Andra James³, Jerome Federspiel⁴, Eugene Kovalik³, Anika Lucas⁴, Laura Neil⁵, Amanda Snyderman³ and Megan Clowse⁶, ¹Duke University, Knightdale, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: The B cell Activating Factor (BAFF) signaling pathway plays an important role in the selection, maturation, and survival of B cells; it consequently contributes…
Abstract Number: 0608 • ACR Convergence 2024
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Chau-Ching Liu⁵, Nicole Wilson⁵, Susan Manzi⁵ and Tyler O'Malley⁶, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Exagen, Vista, CA
Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
Abstract Number: 0625 • ACR Convergence 2024
Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza
Asim Khanfar¹, Shiamak Cooper², Ali Mohamed³, Tanvi Borse⁴ and Sarah Nalwalla⁵, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY, ³Internal Medicine Resident, Rochester General Hospital, Rochester, NY, ⁴Parkview Health, Fort Wayne, IN, ⁵Seth GSMC and KEM Hospital, Mumbai, India
Background/Purpose: SLE is a chronic autoinflammatory condition affecting multiple organ systems. Patients with SLE are at a higher risk for infection compared to the general…
Abstract Number: 0645 • ACR Convergence 2024
Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Samir Patel¹, Zijing Yang¹, deepak Nagra¹, Maryam Adas², Mark Russell¹, Sam Norton¹, Chris Wincup³, James Galloway⁴, Kate Bramham² and Patrick Gordon⁵, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁵nhs, London, United Kingdom
Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…
Abstract Number: 0663 • ACR Convergence 2024
Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study
Arushi Ramnarain¹, Xiaomeng Xu², Joanna Kent³, Sagar Jagtiani⁴, Worawit Louthrenoo⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yi-Hsing Chen⁸, Jiacai Cho⁹, Chiu Wai Shirley Chan¹⁰, Sandra Navarra¹¹, Haihong Yao¹², Lydia Pok¹³, BMDB Basnayake¹⁴, Zhuoli Zhang¹⁵, Madelynn Chan¹⁶, Sang-Cheol Bae¹⁷, Yasuhiro Katsumata¹⁸, Jun Kikuchi¹⁹, Sean O'Neill²⁰, Fiona Goldblatt²¹, Yih Jia Poh²², Mark Sapsford²³, Nicola Tugnet²⁴, Kristine Pek Ling Ng²⁵, Cherica Tee²⁶, Yoshiya Tanaka²⁷, Mandana Nikpour²⁸, Alberta Hoi²⁹, Eric Morand³⁰ and Rangi Kandane-Rathnayake³¹, ¹Monash Health, Melbourne, Victoria, Australia, ²GSK, Value, Evidence & Outcomes, Singapore, Singapore, ³Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, ⁴Glaxo Smith Kline, Singapore, Singapore, ⁵Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ⁹National University Hospital, Singapore, Singapore, ¹⁰Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹¹University of Santo Tomas, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, ¹³University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, ¹⁴Teaching Hospital, Kandy, Sri Lanka, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁹Keio University School of Medicine, Tokyo, Japan, ²⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²SingHealth, Singapore, Singapore, ²³WDHB, Auckland, New Zealand, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Health New Zealand, Auckland, New Zealand, ²⁶Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, ²⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸The University of Sydney, Melbourne, Victoria, Australia, ²⁹Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ³⁰School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ³¹Monash University, Clayton, Victoria, Australia
Background/Purpose: LN is a common and severe manifestation of SLE. Although proteinuria is a useful diagnostic indicator, kidney biopsy is necessary for definitive diagnosis and…
Abstract Number: 0813 • ACR Convergence 2024
Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus
Christina G. Bruxvoort¹, Faith A. Porter¹, Joshua W. Cavett¹, John A. Ice², Batool Bilal¹, R Hal Scofield¹ and Valerie M. Lewis¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OKC Veteran's Affairs Medical Center, Oklahoma City
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that mostlyhas it onset among women between the ages 15–44. While the global pathogenic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].